Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

Co-amoxiclav backed in flu complications

By Alisdair Stirling

Ampicillin, amoxicillin and macrolides may not be as effective against pneumonia and lower respiratory tract infections associated with influenza-like illness as tetracyclines and co-amoxiclav, suggests a major new HPA study.

The findings appear to call into question the agency's own guidelines suggesting GPs should use these antibiotics for treating the respiratory complications of flu and flu-like illness.

Guidelines for the clinical management of patients with influenza-like illness during an influenza pandemic – jointly published in 2007 by the British Infection Society, British Thoracic Society and the HPA in collaboration with the Department of Health – recommend GPs use ampicillin and amoxicillin for treating pneumonia as a complication of flu when S.pneumoniae or H.influenzae ‘is the most likely cause', and recommended macrolides as an alternative to tetracyclines or co-amoxiclav.

The research team from the HPA's centre for infections analysed 86,845 lower respiratory tract specimens - two-thirds of them from GP surgeries and the remainder from outpatients - collected by sentinel laboratories in England, Wales and Northern Ireland between January 2007 and March 2010.

Their analysis showed microbial susceptibility to tetracyclines or co-amoxiclav was high. Of the 70,288 and 45,288 isolates where susceptibility results for tetracyclines or co-amoxiclav were available, 96% and 92% were susceptible, respectively.

However, susceptibility to ampicillin and amoxicillin or macrolides was lower at 77% and 49% respectively and varied markedly with organism, the researchers said.

There were few ‘clinically relevant' variations in susceptibility to tetracyclines such as doxycycline or co-amoxiclav over time, geographically or between age groups.

Lead author Dr Ruth Blackburn, an information analyst in the HPA's department of healthcare-associated infection and antimicrobial resistance concluded: ‘These data clearly indicate that lower respiratory tract isolates of the pathogens studied retain high levels of susceptibility to the antibiotics recommended in the UK guidelines.

‘Susceptibility to ampicillin/amoxicillin and macrolides was well below that recorded for tetracyclines or co-amoxiclav, suggesting that the former drugs are less appropriate for empirical treatment.

‘However, susceptibility to ciprofloxacin for H. influenzae or ampicillin/amoxicillin for S. pneumoniae was high and these antibiotics may be preferable to tetracyclines or co-amoxiclav where the organism is known', she added.

Dr George Kassianos, a GP in Bracknell, Berkshire and RCGP spokesperson for flu and immunisation, said: ‘These studies are very important. This one backs up what I would do, which is to favour co-amoxiclav as first-line treatment and if the infection doesn't clear, to give tetracycline rather than macrolides.'

Co-amoxiclav backed in flu complications

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say